{"id":827657,"date":"2026-07-29T17:31:02","date_gmt":"2026-07-29T17:31:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=827657"},"modified":"2026-07-29T17:31:02","modified_gmt":"2026-07-29T17:31:02","slug":"antibody-therapeutics-market-to-reach-5971-billion-by-2035-driven-by-advances-in-biologics-and-expanding-clinical-applications","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antibody-therapeutics-market-to-reach-5971-billion-by-2035-driven-by-advances-in-biologics-and-expanding-clinical-applications_827657.html","title":{"rendered":"Antibody Therapeutics Market to Reach $597.1 Billion by 2035, Driven by Advances in Biologics and Expanding Clinical Applications"},"content":{"rendered":"
\"Antibody<\/a><\/div>\n
Antibody Therapeutics Market by Product (Commercial, Pipeline), Format (mAb, ADC, Fragment), Target (PDL1, Cytokine), Therapy area (Oncology, Neurology, Inflammatory), Source (Human, Humanized), ROA (IV, SC), Region, Competition – Global Forecast to 2035.<\/div>\n

According to MarketsandMarkets™, <\/strong>The global antibody therapeutics market<\/a><\/strong> is projected to grow from USD 311.2 billion in 2026 to USD 597.1 billion by 2035, at a CAGR of 7.5% during the forecast period. Market growth is driven by the increasing adoption of monoclonal antibodies and next-generation antibody-based therapies across oncology, autoimmune diseases, inflammatory conditions, and other chronic disorders.<\/p>\n

Browse 400 market data Tables and 55 Figures spread through 400 Pages and in-depth TOC on <\/em>“Antibody Therapeutics Market “.<\/strong><\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=178852478<\/a><\/strong><\/p>\n

Rapid advancements in antibody engineering technologies including bispecific antibodies, antibody-drug conjugates (ADCs), Fc optimization, and improved antibody design platforms are accelerating innovation and expanding therapeutic applications. These advancements are enabling more targeted, effective, and personalized treatment approaches, strengthening the role of antibody therapeutics in modern medicine.<\/p>\n

Monoclonal Antibodies Segment Dominates by Format<\/strong><\/p>\n

By format, monoclonal antibodies (mAbs) accounted for the largest share of the antibody therapeutics market in 2025. Their dominance is attributed to a well-established portfolio of approved therapies, broad clinical utility, and strong commercial adoption across multiple disease areas, including oncology, autoimmune disorders, infectious diseases, and inflammatory conditions.<\/p>\n

The continued expansion of mAb pipelines, coupled with improved efficacy and safety profiles, is expected to sustain growth in this segment over the forecast period.<\/p>\n

Hospitals & Specialty Care Centers Lead End-User Segment<\/strong><\/p>\n

By end user, hospitals and specialty care centers accounted for the largest share of the market in 2025. These facilities play a critical role in the administration of complex biologics, including monoclonal antibodies, bispecific antibodies, and ADCs, which often require specialized infrastructure, infusion systems, and close patient monitoring.<\/p>\n

The growing use of antibody therapeutics in oncology, rare diseases, and chronic conditions is further driving demand within hospital and specialty care settings.<\/p>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=178852478<\/a><\/strong><\/p>\n

North America Maintains Market Leadership<\/strong><\/p>\n

North America accounted for the largest share of the antibody therapeutics market in 2025. The region’s dominance is supported by the presence of leading pharmaceutical and biotechnology companies, advanced manufacturing capabilities, and strong regulatory frameworks.<\/p>\n

Supportive approval pathways from regulatory agencies such as the US FDA and Health Canada, along with increasing investments in biologics research and development, are driving continued innovation and commercialization in the region. Strategic collaborations between industry players and academic research institutions are also contributing to market growth.<\/p>\n

Competitive Landscape<\/strong><\/p>\n

Key players operating in the antibody therapeutics market include AbbVie Inc. (US), Merck (US), Novartis AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi (France), Amgen Inc. (US), Regeneron Pharmaceuticals Inc. (US), and Boehringer Ingelheim International GmbH (Germany), among others.<\/p>\n

These companies are focusing on expanding their biologics pipelines, advancing next-generation antibody technologies, and forming strategic partnerships to strengthen their market position and accelerate innovation.<\/p>\n

Related Reports:<\/strong><\/p>\n

Monoclonal Antibody Therapeutics Market<\/a> – Global Forecast to 2029<\/strong><\/p>\n

Antibody Discovery Market<\/a> – Global Forecast to 2030<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Rohan Salgarkar
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City:<\/strong> Florida
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/antibody-therapeutics-market-178852478.html<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Antibody Therapeutics Market by Product (Commercial, Pipeline), Format (mAb, ADC, Fragment), Target (PDL1, Cytokine), Therapy area (Oncology, Neurology, Inflammatory), Source (Human, Humanized), ROA (IV, SC), Region, Competition – Global Forecast to 2035. According to MarketsandMarkets™, The global antibody therapeutics market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,411,404],"tags":[],"class_list":["post-827657","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/827657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=827657"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/827657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=827657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=827657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=827657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}